Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Marker for prognosis prediction of liver cancer based on CD11b and CD169 protein molecules

A technology for CD169 and protein molecules, which is applied in measuring devices, analytical materials, biomaterial analysis, etc., can solve the problems of ignoring the important influence of myeloid cells, high detection cost, and poor accuracy, and achieve simple and convenient detection methods with high clinical Application value, high sensitivity effect

Inactive Publication Date: 2020-05-08
SUN YAT SEN UNIV
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Most of the newly proposed immune-related markers have not been verified by multi-center and large-sample data, and there is a possibility of over-fitting the clinical sample data used. The reliability of large-scale use is doubtful, and the effectiveness of judging the prognosis of patients is low. The accuracy is poor; at the same time, lymphocyte markers (such as CD3, CD8, Granzyme B, Foxp3, etc.) are mostly used for multiple indicators to indicate the immune response in liver cancer and predict the prognosis of patients, while ignoring the importance of myeloid cells for the prognosis and prognosis of patients. Significant impact of anticancer therapy
At the same time, at present, for the combination of markers and the prediction model to accurately predict the prognosis of liver cancer, it is generally necessary to use high-throughput technologies such as gene expression chips, gene methylation chips, and RNA sequencing. The detection costs are high, and many indicators are included in the final model. , not conducive to clinical promotion and use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marker for prognosis prediction of liver cancer based on CD11b and CD169 protein molecules
  • Marker for prognosis prediction of liver cancer based on CD11b and CD169 protein molecules
  • Marker for prognosis prediction of liver cancer based on CD11b and CD169 protein molecules

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1 Calculation of Myeloid Response Score (hereinafter referred to as MRS)

[0051] The present invention selects two protein molecular markers (CD11b and CD169) of myeloid immune cells. Among them, CD11b is used to mark CD11b + Myeloid cells (mainly CD11b + granulocytes, monocytes, myeloid-derived suppressor cells, etc.); CD169 for labeling CD169 + Myeloid cells (mainly CD169 + monocytes / macrophages).

[0052] 1. Immunohistochemical staining

[0053] The specific dyeing process is as follows:

[0054] (1) Select liver cancer tissue wax blocks to ensure that there is enough cancer nest area for statistics and no large tissue necrosis;

[0055] (2) Obtain a 4 μm paraffin section, bake it at 60°C for 2 hours, take it out, and cool it slightly;

[0056] (3) Dewaxing with xylene twice at room temperature, 10 minutes each time;

[0057] (4) Wash away the xylene in 100% ethanol, and then pass through 95% alcohol, 80% alcohol, and 70% alcohol successively, each t...

Embodiment 2

[0088] Example 2 Myeloid Response Score MRS can be used as the basis for grouping patients with liver cancer

[0089] 1. MRS as the basis for grouping patients in the initial sample set-training subset

[0090] 1. Selection of initial sample set-training subset samples

[0091] The primary cohort consisted of 488 paraffin-archived specimens from patients with liver cancer who underwent tumor resection for the first time at Sun Yat-sen University Cancer Hospital from January 2006 to December 2008, including liver cancer tumor tissues and matched distant paracancerous tissues. Normal tissue (more than 2cm away from the tumor area). The batch of patients was randomly divided into two groups, namely 244 cases of training set (primary-training cohort) and 244 cases of verification set (primary-test cohort), for subsequent model construction. All the above selected patients were not co-infected with syphilis, HIV virus or suffering from autoimmune diseases. None of the patients r...

Embodiment 3

[0112] Example 3 MRS predicts the curative effect of sorafenib treatment after relapse in patients

[0113] 1. Experimental method

[0114] In a cohort of 56 patients who had previously undergone radical resection of liver cancer and received sorafenib 800 mg daily after recurrence diagnosis, recurrence occurred 0.8 to 121.4 months after tumor resection (interquartile range, 4.9 to 30.1 months) , Sorafenib treatment time ranged from 1.7 to 60.8 months (interquartile range, 6.3 to 21.4 months).

[0115] After using the same standard to group patients according to MRS value (low MRS: 0≤MRS≤37.9; medium MRS: 37.9<MRS≤60.6; high MRS: 60.6<MRS≤100), the patients were divided according to their overall survival after treatment. Sort and mark the curative effect evaluation at each time point.

[0116] 2. Experimental results

[0117] Compared with the other two groups, HCC patients in the MRS-low group tended to obtain longer post-treatment survival and had the best response to so...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a marker for prognosis prediction of liver cancer based on CD11b and CD169 protein molecules. The marker is MRS, and the MRS=0.161*CD11bT-0. 106*CD169T+35. According to the MRSprovided by the invention, a marker of myeloid cells instead of a marker of lymphocytes is utilized; the prediction ability of postoperative recurrence and survival of a patient undergoes multi-center and large-sample verification, and the reliability is higher; the marker can further be used for predicting the curative effect of subsequent sorafenib or TACE treatment on postoperative recurrent patients; prognostic indexes with high prognosis specificity, high sensitivity and high clinical application value can be obtained only by detecting the CD11b+cell density and the CD169+cell density inthe liver cancer tissue, and the detection method is simple and convenient.

Description

technical field [0001] The present invention relates to the technical field of liver cancer prognosis prediction, more specifically, to a marker for liver cancer prognosis prediction based on CD11b and CD169 protein molecules Background technique [0002] Hepatocellular carcinoma (liver cancer for short) is one of the most common cancers in the world. The incidence of liver cancer in my country has remained high for a long time, the early diagnosis rate is less than 30%, and the 5-year relative survival rate is only 10.1%. At present, the clinical treatment methods for liver cancer are still very limited, and radical resection is still the main treatment option for patients with liver cancer in my country. In this context, the establishment of prognostic indicators after liver cancer surgery is the key to judging the risk of recurrence in patients with liver cancer after surgery, early intervention in further deterioration of the disease, and avoiding unnecessary treatment ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
CPCG01N33/57484G01N33/57438G01N33/56966G01N2800/52
Inventor 郑利民吴翀林洁陈敏山徐立
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com